The UCI Blood Donor Center is now offering free COVID-19 antibody testing for qualified donors who donate blood or platelets. This is exclusively available at the donor center in Orange, not at mobile drives. Testing is open to all, not just UCI employees. Antibody testing does not diagnose a current case of COVID. It may help determine whether a person was previously infected, but not in all cases. Please read this Q & A to better understand the COVID antibody test. The blood donor center is located in Pavilion 3 next to Occupational Health. Hours are Mon., Tues., Thurs., Fri.…
Read More
The Alzheimer’s Impact Movement and Alzheimer’s Association need your advocacy support: The Promoting Alzheimer’s Awareness to Prevent Elder Abuse Act (H.R. 6813/S.3703) is critical legislation which would require the Department of Justice to develop training materials to assist professionals who support victims of abuse living with Alzheimer’s and other dementia in order to improve the quality of their interactions with this vulnerable population and help protect them from elder abuse. Support for this legislation has been growing, but to keep up the momentum, it is critical that your Senators hear from you today. Please ask your Senators to co-sponsor and pass…
Read More
Contributed by Hayk Davtyan, PhD Vaccines have become one of the most discussed topics during the COVID-19 pandemic. From development to distribution, the whole world has their eyes on a new vaccine. However, promising new data has now brought common vaccines even to the forefront of discussion in the study of Alzheimer’s disease (AD). At the 2020 Alzheimer’s Association International Conference this week (#AAIC20), newly presented data shows how flu and pneumonia vaccines may lower the risk for Alzheimer’s disease (AD). Hayk Davtyan, PhD Previous studies have shown the possible connection between vaccination and reducing cognitive decline. Yet, there has…
Read More
Dr. Ahmad Sajjadi UCI MIND faculty member, Ahmad Sajjadi, MD, PhD, was recently named a member of the Alzheimer’s Clinical Trials Consortium (ACTC) Early Career Project Evaluation Committee (PEC). The ACTC is a clinical trials network designed to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. UCI MIND has been a member of the ACTC network since its inception in 2018. The PEC of the ACTC is an important early first step in determining what trials the network will take on and in this initiative will provide mentorship for early career members. Dr. Sajjadi is an Assistant…
Read More
#AAIC20 kicks off today! A virtual week-long international conference covering the latest topics in #Alzheimers and #dementia science and healthcare. Today, Dr. Vivek Swarup from UCI MIND led a discussion on #genetics and omics of Alzheimer’s – his presentation available On Demand at AAIC: aaic2020.vfairs.com
Read More
HealthDay - July 22, 2020 Maria Corrada, a professor of epidemiology at the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine (UCI MIND), said, "Some of the characteristics found to be related to resistance and resilience to Alzheimer's pathology can be changed or modified -- pulse pressure, smoking, paid work and life satisfaction." … "We believe that there are things we can do with our lifestyle that can help us maintain good cognitive health," she said.
Read More
The University of California, Irvine Institute for Memory Impairments and Neurological Disorders (UCI MIND) is leading a new annual multi-day course on clinical trials in Alzheimer’s disease and related dementias. Josh GrillPhoto: Steve Zylius/UCI The course will be directed by Joshua Grill, PhD, Director of UCI MIND and Rema Raman, PhD, a professor of neurology at the Keck School and the Director of Biostatistics at USC Alzheimer’s Therapeutic Research Institute (ATRI). Other course faculty members include UCI MIND researchers Daniel Gillen, PhD and David Sultzer, MD. The launch of the training program, called IMPACT-AD, is designed to educate and promote…
Read More
Contributed by UCI MIND faculty member Kei Igarashi, PhD. In a paper recently published in Neuron, our lab found for the first time that “remapping” of hippocampus place cells, a brain circuit function to distinguish distinct environments, is disrupted in an Alzheimer’s disease mouse model. Our work suggests that remapping impairment is a circuit mechanism causing spatial memory impairment in Alzheimer’s disease. We hope that, by developing methods to reactivate remapping, we can develop new treatments for spacial memory impairment in Alzheimer’s disease patients in a near future.
Read More
20 percent more than last year, the total reflects strong support for campus mission Irvine, Calif., July 20, 2020 — From cutting-edge research and clinical trials focused on cancer care to creating a new center devoted to protecting personal data privacy, University of California, Irvine scholars, scientists and physicians are blazing new paths to help change the world. And their impact keeps growing. In fiscal 2019-20, which ended June 30, UCI researchers received the most funding in campus history: $529 million in grants and contracts. Awards from federal and state agencies, leading foundations and forward-thinking companies increased by 20 percent…
Read More
Join UCI MIND and Alzheimer's Orange County for the 31st Annual Southern California Alzheimer’s Disease Research Conference: "Tackling Dementia with Technology" Thursday, September 10, 2020 | 8:00 am - 12:00 pm PST Live on YouTube & Facebook International experts will discuss how new technology is being used to accelerate science and care for Alzheimer's disease and related dementias. This free virtual conference welcomes healthcare providers, senior/social service providers, patients and families, researchers, students, and anyone eager to learn. Click here to learn more and register: https://conference.mind.uci.edu
Read More
